GlycoMimetics, Inc. (NASDAQ:GLYC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On June 9, 2017, the Board of Directors (the Board) of
GlycoMimetics, Inc. (the Registrant) appointed Patricia S.
Andrewsto serve as a director of the Company and a member of the
Audit Committee of the Board.Ms. Andrews will serve as a Class
III director whose term will expire at the 2020 annual meeting of
stockholders. There is no arrangement or understanding between
Ms. Andrews and any other person to which she was selected as a
director of the Company, and there is no family relationship
between Ms. Andrews and any of the Companys other directors or
executive officers.The Company is not aware of any transaction
involving Ms. Andrews requiring disclosure under Item 404(a) of
Regulation S-K. Additional information about Ms. Andrews is set
forth below.

Patricia S. Andrews, age 59, has served as a member of our Board
since June 2017.Ms. Andrews has served as Chief Executive Officer
of Boston Biomedical, Inc., an oncology drug research and
development company, since April 2017 and previously served as
its Chief Operating Officer from November 2013 to April 2017.From
October 2008 to August 2012, Ms. Andrews served as Chief
Commercial Officer of Incyte Corporation, a publicly held
biopharmaceutical company.From 1991 to 2008, Ms. Andrews served
in various roles of increasing responsibility at Pfizer Inc.,
culminating in her role as Vice President and General Manager of
Pfizers U.S. Oncology business unit.Ms. Andrews received her B.A.
degree from Brown University and her M.B.A. degree in Finance
from the University of Michigan.

In accordance with the Companys compensation policy for
non-employee directors, upon her appointment as a director, Ms.
Andrews was granted a nonqualified stock option to purchase
22,000 shares of the Companys common stock at an exercise price
of $11.63, the closing price of the Companys common stock on the
date of grant.This option will vest and become exercisable in
three equal installments on the first, second and third
anniversaries of the date of grant, subject to Ms. Andrewss
Continuous Service (as defined in the Companys 2013 Equity
Incentive Plan) as of each vesting date.Additionally, Ms. Andrews
will be entitled to receive a $35,000 annual retainer for her
service as director and a $7,500 annual retainer for her service
on the Audit Committee.At each annual stockholder meeting
following which Ms. Andrewss term as a director continues, Ms.
Andrews will be entitled to receive an additional nonqualified
stock option to purchase 11,000 shares of the Companys common
stock, which option will vest and become exercisable over a
one-year period following the date of grant.Ms. Andrews has also
entered into the Companys standard form of indemnification
agreement.

Item 7.01 Regulation FD Disclosure.

On June 12, 2017, the Company issued a press release announcing
Ms. Andrewss appointment to the Board. A copy of this press
release is furnished herewith as Exhibit99.1 to this Current
Report. The information contained in the press release furnished
as Exhibit 99.1 shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), and is not incorporated by reference into any of
the Companys filings under the Securities Act of 1933, as
amended, or the Exchange Act, whether made before or after the
date hereof, except as shall be expressly set forth by specific
reference in any such filing.

Item 9.01 Exhibits.

(d)Exhibits

About GlycoMimetics, Inc. (NASDAQ:GLYC)

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.